ClinicalTrials.gg
Active, not recruitingNCT06771622Updated Feb 4, 2026

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of HCB101 and Trastuzumab in Solid Cancer, sponsored by FBD Biologics Limited. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.

Sponsored by FBD Biologics Limited · Phase 1/2, Interventional, and Treatment

How we know · 39 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
500
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a non-randomized, open-label, dose-escalation, and dose-expansion Phase Ib/IIa study to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity of HCB101 administered in combination with standard or approved anticancer therapies in subjects with advanced solid tumors. The trial includes a Part-I (Phase Ib) of the dose-escalation phase and a Part-II (Phase IIa) of the dose-expansion phase.

Part-I: Dose-escalation phase (Phase Ib):

Part I uses a standard 3+3 dose-escalation design to characterize safety and tolerability and to determine the maximum tolerated dose (MTD) and/or recommended Phase II dose (RP2D) of HCB101 when administered in combination regimens. The study includes 14 planned cohorts (Cohorts 1-9, including sub-cohorts 3a-3d and 6a-6c).

Part-II: Dose-expansion phase (Phase IIa) Based on safety, tolerability, PK/PD, and emerging antitumor activity observed in Part-I (Phase Ib), selected dose levels, tumor types, and combination regimens will be further investigated in Part-II (Phase IIa).

02

Conditions studied

  • Solid Cancer
03

In context

Lead sponsor

FBD Biologics Limited is the lead sponsor of 4 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects are able to understand and willing to provide signed .
  2. Male and female subjects of ≥18 years of age, inclusive, at the time of signing the informed consent.
  3. With histologically/ confirmed diagnosis of advanced solid tumors as described below:

1) Cohort 1- Gastric Cancer, HER-Positive (): 2) Cohort 2 - Gastric Cancer (Second-Line): 3) Cohort 3 - Colorectal Cancer (Second-Line): 4) Cohort 4 - Triple-Negative Breast Cancer (First-Line): 5) Cohort 5 - Gastric Cancer, Medium/Low/Negative (First-Line): 6) Cohort 6 - Head and Neck Squamous Cell Carcinoma: 7) Cohort 7 - Ovarian Cancer: 8) Cohort 8 - Hepatocellular Carcinoma: 9) Cohort 9 - Extensive-Stage Small Cell Lung Cancer: 4. Have adequate organ function, as indicated by the following laboratory parameters below (had not received a blood transfusion, apheresis infusion, erythropoietin, granulocyte colony-stimulating factor, and other relevant medical support within 14 days before the administration of the first dose of study intervention).

Exclusion criteria

Exclusion Criteria:

  1. With a known history of to any components of the study intervention.
  2. Prior/Concomitant Therapy/Treatment:

    1. Subjects who have undergone major surgery or radical radiotherapy within 28 days before the first dose of study intervention.
    2. Subjects who have received systemic antitumor therapies within the following prior to the first dose of study intervention:

      • 28 days for curative radiotherapy, immunotherapy, or targeted therapy, etc.
      • 14 days for chemotherapy, palliative radiotherapy, endocrine therapy, or herbal medicine or traditional therapies with known or claimed antitumor activity.
    3. Subjects who have used a radioactive drug (Strontium, Samarium, etc.) within 56 days before the first dose of the study intervention.
    4. Subjects who are active using of vitamin K antagonist anticoagulant like warfarin. Use of low molecular weight heparin and factor Xa inhibitors will be permitted on a case-by-case basis. Daily low dose of aspirin use (≤ 100 mg QD in Mainland China; ≤ 81 mg QD in the United States) is allowed.
    5. Subjects who have received any treatment targeting the 7 or SIRPα pathway.
    6. Subjects who have received or plan to receive live virus or bacterial vaccine within 28 days before the first dose of study intervention while the subject receives the study intervention.
  3. Participation in another clinical study with an product administered or investigational device used in the last 28 days (If half-life is not clear) or 5 half-lives (If half-life is clear, the longer time one prevails) before receiving the first dose of study intervention.
  4. Subjects who have received any treatment targeting the CD47 or SIRPα pathway.
  5. An uncontrolled acute infection.
  6. Known to have a history of alcoholism or drug abuse.
  7. Any other medical (e.g., class B or C, pulmonary, metabolic, congenital, endocrinal or CNS disease, etc.), psychiatric, or social condition deemed by the Investigator to be likely to interfere with a subject's rights, safety, welfare or ability to sign , cooperate and participate in the study, or interfere with the interpretation of the results.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
500 participants (estimated)

Study arms

  • Experimental
    Cohort 1: HCB101+Trastuzumab+Pertuzumab+CAPEOX

    HCB101: QW Trastuzumab: 8 mg/kg IV loading dose on Day 1 of cycle 1, then 6 mg/kg IV every 21 days; Pertuzumab: 840 mg IV on Day 1, cycled every 21 days; Oxaliplatin: 130 mg/m2 IV on Day 1, cycled every 21 days; Capecitabine: 1000 mg/m2 PO BID on Days 1-14, cycled every 21 days;

    Drug: HCB101 · Drug: Trastuzumab · Drug: Pertuzumab · Drug: Oxaliplatin · Drug: Capecitabine

  • Experimental
    Cohort 2: HCB101+Ramucirumab+Paclitaxel

    HCB101: QW Ramucirumab: 8 mg/kg IV on Days 1 and 15, cycled every 28 days; Paclitaxel: 80 mg/m2 IV on Days 1, 8, and 15, cycled every 28 days;

    Drug: HCB101 · Drug: Ramucirumab · Drug: Paclitaxel

  • Experimental
    Cohort 3a: HCB101 + Bevacizumab + FOLFIRI/ mFOLFOX6

    HCB101: QW Bevacizumab 5 mg/kg IV on D1, Q2W FOLFIRI: Irinotecan 180 mg/m2 IV on D1, Q2W Leucovorin 400 mg/m2 IV on D1, Q2W 5-FU 400 mg/m2 IV on D1, then 1200 mg/m2/day on D2 and D3 (total 2400 mg/m2), Q2W mFOLFOX6: Oxaliplatin 85 mg/m2 IV on D1, Q2W Leucovorin 400 mg/m2 IV on D1, Q2W 5-FU 400 mg/m2 IV on D1, then 1200 mg/m2/day on D2 and D3 (total 2400 mg/m2), Q2W

    Drug: HCB101 · Drug: Oxaliplatin · Drug: Bevacizumab · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-FU · Drug: Pembrolizumab

  • Experimental
    Cohort 3b: HCB101 + Cetuximab + FOLFIRI/ mFOLFOX6

    HCB101: QW Cetuximab 400 mg/m2 IV on D1, then 250 mg/m2, weekly FOLFIRI: Irinotecan 180 mg/m2 IV on D1, Q2W Leucovorin 400 mg/m2 IV on D1, Q2W 5-FU 400 mg/m2 IV on D1, then 1200 mg/m2/day on D2 and D3 (total 2400 mg/m2), Q2W mFOLFOX6: Oxaliplatin 85 mg/m2 IV on D1, Q2W Leucovorin 400 mg/m2 IV on D1, Q2W 5-FU 400 mg/m2 IV on D1, then 1200 mg/m2/day on D2 and D3 (total 2400 mg/m2), Q2W

    Drug: HCB101 · Drug: Oxaliplatin · Drug: Cetuximab · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-FU

  • Experimental
    Cohort 3c: HCB101 + Ramucirumab + FOLFIRI

    HCB101: QW Ramucirumab 8 mg/kg IV on D1 and 15, Q4W FOLFIRI: Irinotecan 180 mg/m2 IV on D1, Q2W Leucovorin 400 mg/m2 IV on D1, Q2W 5-FU 400 mg/m2 IV on D1, then 1200 mg/m2/day on D2 and D3 (total 2400 mg/m2), Q2W

    Drug: HCB101 · Drug: Ramucirumab · Drug: Irinotecan · Drug: Leucovorin · Drug: 5-FU

  • Experimental
    Cohort 3d: HCB101 + mFOLFOX6

    HCB101: QW mFOLFOX6: Oxaliplatin 85 mg/m2 IV on D1, Q2W Leucovorin 400 mg/m2 IV on D1, Q2W 5-FU 400 mg/m2 IV on D1, then 1200 mg/m2/day on D2 and D3 (total 2400 mg/m2), Q2W

    Drug: HCB101 · Drug: Oxaliplatin · Drug: Leucovorin · Drug: 5-FU

  • Experimental
    Cohort 4: HCB101 + Pembrolizumab/Toripalimab + albumin-bound paclitaxel

    HCB101, QW Pembrolizumab 200 mg IV on D1, Q3W or Toripalimab 240 mg IV on D1, Q3W Albumin-bound paclitaxel 100 mg/m2 on D1, 8, 15, Q4W or 125 mg/m2 IV on D1, D8, Q3W

    Drug: HCB101 · Drug: Toripalimab · Drug: Albumin-bound paclitaxel · Drug: Pembrolizumab

  • Experimental
    Cohort 5: HCB101 + Pembrolizumab + CAPEOX

    HCB101, QW Pembrolizumab 200 mg IV on D1, Q3W Oxaliplatin 130 mg/m2 IV on D1, Q3W Capecitabine 1000 mg/m2 PO BID on D1-14, Q3W

    Drug: HCB101 · Drug: Oxaliplatin · Drug: Capecitabine · Drug: Pembrolizumab

  • Experimental
    Cohort 6a: HCB101 + Pembrolizumab

    HCB101, QW Pembrolizumab 200 mg IV on D1, Q3W

    Drug: HCB101 · Drug: Pembrolizumab

  • Experimental
    Cohort 6b: HCB101 + Pembrolizumab + Cetuximab

    HCB101, QW Pembrolizumab 200 mg IV on D1, Q3W Cetuximab 400 mg/m2 IV on D1, then 250 mg/m2, QW

    Drug: HCB101 · Drug: Cetuximab · Drug: Pembrolizumab

  • Experimental
    Cohort 6c: HCB101 + Cetuximab

    HCB101, QW Cetuximab 400 mg/m2 IV on D1, then 250 mg/m2, QW

    Drug: HCB101 · Drug: Cetuximab

  • Experimental
    Cohort 7: HCB101 + Trastuzumab Deruxtecan

    HCB101, QW Trastuzumab Deruxtecan 5.4 mg/kg IV on D1, Q3W

    Drug: HCB101 · Drug: Trastuzumab deruxtecan

  • Experimental
    Cohort 8: HCB101 + Atezolizumab/Toripalimab + Bevacizumab

    HCB101, QW Atezolizumab 1200 mg IV on D1, Q3W or Toripalimab 240 mg IV on D1, Q3W Bevacizumab 15 mg/kg IV on D1, Q3W

    Drug: HCB101 · Drug: Bevacizumab · Drug: Toripalimab · Drug: Atezolizumab

  • Experimental
    Cohort 9: HCB101 + Atezolizumab/Toripalimab + carboplatin + etoposide.

    HCB101, QW Atezolizumab 1200 mg IV on D1, Q3W or Toripalimab 240 mg IV on D1, Q3W Carboplatin AUC=5, IV on D1, Q3W for 4 cycles Etoposide 100mg/m2, IV on D1, 2, 3, Q3W for 4 cycles

    Drug: HCB101 · Drug: Toripalimab · Drug: Carboplatin (AUC 5) · Drug: Etoposide · Drug: Atezolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number/incidence and percentage of subjects with adverse events.

    To evaluate the safety and tolerability of HCB101

    Time frame: 12 months

  2. Number of subjects with Maximal tolerance dose (MTD) of HCB101

    To evaluate the tolerability of HCB101

    Time frame: 12 months

Secondary outcomes

  1. Overall Rate Response (ORR)

    ORR is defined as the proportion of participants who have a partial response (PR) or critical response (CR)

    Time frame: 12 months

  2. Duration of Response (DoR)

    DOR is defined as time from date of initial documentation of a response (PR or CR) to date of first documented evidence of progressive disease (PD)

    Time frame: 12 months

  3. Disease Control Rate (DCR)

    DCR is defined as the proportion of participants who have a partial response (PR), critical response (CR), or disease stable (SD)

    Time frame: 12 months

  4. Progression-Free Survival (PFS)

    Defined as the duration from the start of treatment until tumor progression or death of any cause.

    Time frame: 12 months

  5. Peak Plasma Concentration (Cmax) of HCB101

    Peak Plasma Concentration (Cmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels.

    Time frame: 12 months

  6. Area under the plasma concentration versus time curve (AUC) of HCB101

    Area under the plasma concentration versus time curve (AUC) of HCB101

    Time frame: 12 months

  7. Time to maximum drug concentration in plasma (Tmax) of HCB101

    Time to maximum drug concentration in plasma (Tmax) of HCB101 following single and repeated IV doses of HCB101 at different dose levels.

    Time frame: 12 months

  8. Terminal elimination half-life (t1/2) of HCB101

    Terminal elimination half-life (t1/2) of HCB101 following single and repeated IV doses of HCB101 at different dose levels.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Jan 2028, 33 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 8, 2025
First posted
Jan 13, 2025
StartActual
Mar 13, 2025
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2029
Last update
Feb 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06771622
Lead sponsor
FBD Biologics Limited
Responsible party
Sponsor
First posted
Jan 13, 2025
Start date
Mar 13, 2025
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2029 (estimated)
Last update
Feb 4, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SIRP-alpha-Fc Fusion Protein HCB101

Start the discussion